Prescription medicine
Lasmiditan Brand names: Reyvow
Lasmiditan (Reyvow) is a prescription medicine with an FDA approval on record since 2019. No generic is listed; pharmacies paid $88.77 per Reyvow 100 mg tablet in the October 7, 2026 NADAC survey.
- No generic listed
- A presentation discontinued
- DEA Schedule V
Check it at the source: the lasmiditan FDA label on DailyMed (effective January 8, 2026, Eli Lilly and Company); the NDA 211280 record on Drugs@FDA; every lasmiditan label on DailyMed.
Highlights of the record
FDA label of January 8, 2026; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026; NADAC October 7, 2026
Used for
From the label: indications and usageREYVOW ® is indicated for the acute treatment of migraine with or without aura in adults.
Forms and strengths
- 50 mg
- 100 mg
Tablet.
On the market
- Earliest approval on file
- October 11, 2019 Reyvow, Eli Lilly And Co; Drugs@FDA’s file, where older or withdrawn approvals can be missing
- Generic approvals
- No generic approved
- Labelers listed (NDC)
- 1 of which 0 under generic applications, 1 under brand applications, repackagers included
- Last listed patent
- July 6, 2040 Reyvow tablets; not a generic launch date
Supply and safety
- Pharmacy cost (NADAC)
- $88.77 per tablet Reyvow 100 mg tablet
- Shortage (FDA)
- None current 6 past records
- Recalls by its makers (FDA)
- No recall recorded
- FAERS reports
- 1,143 through July 30, 2026
What is lasmiditan used for?
From the label: indications and usageREYVOW ® is indicated for the acute treatment of migraine with or without aura in adults. REYVOW ® is a serotonin (5-HT) 1F receptor agonist indicated for the acute treatment of migraine with or without aura in adults. ( 1 ) Limitations of Use REYVOW is not indicated for the preventive treatment of migraine. ( 1 ) Limitations of Use REYVOW is not indicated for the preventive treatment of migraine.
Conditions named in the indications of lasmiditan's FDA labels, with every medicine labeled for each:
Source: FDA drug label (Reyvow), Eli Lilly and Company, effective January 8, 2026 (SPL set aea3358c-ff41-4490-9e6d-c7bf7b3de13f), via openFDA; the full label on DailyMed
What does the patient leaflet for lasmiditan say first?
The FDA-approved Medication Guide or Patient Information that comes with the medicine, in its own words.
From the patient leaflet: What is the most important information I should know about REYVOW?Do not drive or operate machinery for at least 8 hours after you take REYVOW, even if you feel well enough. You should not take REYVOW if you cannot wait at least 8 hours between taking REYVOW and driving or operating machinery.
From the patient leaflet: What should I avoid while taking REYVOW?Do not drive or operate machinery for at least 8 hours after taking REYVOW. You should not drink alcohol or take other medicines that make you drowsy while taking REYVOW.
From the patient leaflet: How should I store REYVOW?Store REYVOW at room temperature between 68°F to 77°F (20°C to 25°C). Keep REYVOW and all medicines out of the reach of children.
Source: FDA drug label (Reyvow), Eli Lilly and Company, effective January 8, 2026 (SPL set aea3358c-ff41-4490-9e6d-c7bf7b3de13f), via openFDA; the full label on DailyMed
Is there a generic for lasmiditan (Reyvow)?
No generic lasmiditan is approved (Drugs@FDA, October 8, 2026). Drugs@FDA also holds 2 tentative approvals: the FDA found the generic approvable, but patents or exclusivity keep it from final approval for now.
The Orange Book lists 4 patents for Reyvow tablets: the compound patent runs to December 5, 2037, and the last listed entry to July 6, 2040. A patent or exclusivity date is not the date a generic goes on sale: court cases and settlements move it either way.
- 2019 earliest approval on file
- 2040 last listed patent
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What do pharmacies pay for lasmiditan (Reyvow)?
In CMS's NADAC survey of October 7, 2026, pharmacies paid $88.77 per Reyvow 100 mg tablet, about the same as a year earlier. The chart's scale runs from the lowest to the highest price shown, not from zero. NADAC is what retail pharmacies paid their wholesalers, per unit, in CMS's monthly survey; what a patient pays depends on insurance and the pharmacy.
- Reyvow 50 mg tablet (brand)
| Strength and form | Brand or generic | Pharmacy cost | 30 tablets, or one pen or vial | 12-month change |
|---|---|---|---|---|
| Reyvow 100 mg tablet | Brand | $88.77 per tablet | $2,663.14 | -0.1% |
| Reyvow 50 mg tablet | Brand | $88.70 per tablet | $2,660.92 | no change |
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price
Is lasmiditan in shortage?
No lasmiditan presentation is listed as in shortage in the FDA Drug Shortage Database (read October 8, 2026); its 6 records are all marked to be discontinued, the latest updated November 3, 2025. ASHP keeps a separate shortage list, which can differ.
| Presentation | Company | Status | Updated |
|---|---|---|---|
| Reyvow, Tablet, 100 mg (NDC 0002-4491-08) | Eli Lilly and Co. | To Be Discontinued | November 3, 2025 |
| Reyvow, Tablet, 100 mg (NDC 0002-4491-61) | Eli Lilly and Co. | To Be Discontinued | November 3, 2025 |
| Reyvow, Tablet, 100 mg (NDC 0002-4491-62) | Eli Lilly and Co. | To Be Discontinued | November 3, 2025 |
| Reyvow, Tablet, 50 mg (NDC 0002-4312-08) | Eli Lilly and Co. | To Be Discontinued | November 3, 2025 |
| Reyvow, Tablet, 50 mg (NDC 0002-4312-61) | Eli Lilly and Co. | To Be Discontinued | November 3, 2025 |
| Reyvow, Tablet, 50 mg (NDC 0002-4312-62) | Eli Lilly and Co. | To Be Discontinued | November 3, 2025 |
Source: FDA Drug Shortage Database via openFDA, updated October 8, 2026
What does the lasmiditan label say about other medicines?
The lasmiditan label names 4 other medicines in its interaction, contraindication or warning sections. The sentences are the labels' own; a label lists what its studies and reports found, not every interaction.
| Medicine named | Section | What the label says |
|---|---|---|
| Dextromethorphan | drug interactions | Concomitant administration of REYVOW and drugs (e.g., SSRIs, SNRIs, TCAs, MAO inhibitors, trazodone, etc.), over-the counter medications (e.g., dextromethorphan), or herbal supplements (e.g., St. John's Wort) that increase serotonin may increase the risk of serotonin syndrome [see Warnings and Precautions ( 5.3 )]. |
| Digoxin | drug interactions | P-glycoprotein (P-gp) Transporter Substrates Coadministration of REYVOW with P-gp substrates where a small change in substrate plasma concentration may lead to serious toxicities (e.g., digoxin) is not recommended [see Clinical Pharmacology ( 12.3 )]. |
| Propranolol | drug interactions | In a drug interaction study, addition of a single 200 mg dose of REYVOW to propranolol decreased heart rate by an additional 5 beats per minute compared to propranolol alone, for a mean maximum of 19 beats per minute. |
| Trazodone | drug interactions | Concomitant administration of REYVOW and drugs (e.g., SSRIs, SNRIs, TCAs, MAO inhibitors, trazodone, etc.), over-the counter medications (e.g., dextromethorphan), or herbal supplements (e.g., St. John's Wort) that increase serotonin may increase the risk of serotonin syndrome [see Warnings and Precautions ( 5.3 )]. |
Source: FDA drug label (Reyvow), Eli Lilly and Company, effective January 8, 2026 (SPL set aea3358c-ff41-4490-9e6d-c7bf7b3de13f), via openFDA; the full label on DailyMed
What do FAERS reports show for lasmiditan?
The FDA Adverse Event Reporting System holds 1,143 reports that list lasmiditan among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 13 are coded as a death and 58 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.
Reports received each year
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
What else is labeled for the same conditions as lasmiditan?
12 other medicines are given the same way (oral) and in the same FDA class as lasmiditan or labeled mainly for the same use (migraine), the same class first. Migraine lists all 27 medicines labeled for it, by any route. The first 8 are below. They are listed as records, not as substitutes: whether one can replace another is a prescriber's decision.
| Medicine | Shared indication | Generic labelers (oral) | Pharmacy cost | Shortage |
|---|---|---|---|---|
| Sumatriptan | Migraine | 22 labelers | $0.302 per tablet 50 mg tablet | No current entry |
| Rizatriptan | Migraine | 25 labelers | $0.335 per tablet 10 mg tablet | No current entry |
| Zolmitriptan | Migraine | 18 labelers | $1.02 per tablet 2.5 mg tablet | No current entry |
| Eletriptan | Migraine | 10 labelers | $1.75 per tablet 40 mg tablet | No current entry |
| Naratriptan | Migraine | 4 labelers | $1.08 per tablet 2.5 mg tablet | No current entry |
| Almotriptan | Migraine | 3 labelers | $16.86 per tablet 12.5 mg tablet | No current entry |
| Naproxen and sumatriptan | Migraine | 3 labelers | $10.46 per unit 85-500 mg | No current entry |
| Frovatriptan | Migraine | 4 labelers | $2.72 per tablet 2.5 mg tablet | A presentation being discontinued |
Every medicine labeled for the same conditions as lasmiditan
Source: FDA drug labels (indications), NDC Directory, NADAC of October 7, 2026, FDA shortages (October 8, 2026)
What next?
- Alternatives to lasmiditan
- 12 medicines for the same use
- Lasmiditan side effects
- the label's list beside FAERS reports
- Lasmiditan shortage record
- every presentation, company and date
- Check an interaction
- what two or more labels say about each other